A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT07664553
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT07664553 -
2025-523935-20-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Bulgaria, Canada, China, Czechia, Germany, India, Japan, Malaysia, Poland, South Korea, Thailand
- Registry status
- Recruiting
Technical summary
Registry record NCT07664553. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2028-05-23 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
- Acronym
- Eluminate-3
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07664553- Content hash
79a580c9e31a413947d81246d3fa290a648efbd3d908621da80b09cfad9564c4